Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GGT1 | P19440 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | ARG1 | P05089 | 1/20 | 0.50 |
| ▸ | ARG2 | P78540 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200536 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MEN1CYP1A2KMT2AGGT1 | |
| SCHEMBL200537 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MEN1CYP1A2KMT2AGGT1 | |
| Water SCHEMBL434488 | 0.98 | ALDH1A1 (0.54) | ALDH1A1MEN1CYP1A2KMT2AGGT1 | |
| Water SCHEMBL10780975 | 0.98 | ALDH1A1 (0.54) | ALDH1A1MEN1CYP1A2KMT2AGGT1 | |
| Water SCHEMBL10780977 | 0.98 | ALDH1A1 (0.54) | ALDH1A1MEN1CYP1A2KMT2AGGT1 | |
| SCHEMBL1300781 | 0.86 | ARG1 (0.57) | ALDH1A1MEN1CYP1A2KMT2AGGT1 | |
| SCHEMBL9003618 | 0.86 | ARG1 (0.57) | ALDH1A1MEN1CYP1A2KMT2AGGT1 | |
| 1-Aminocyclopropane Carboxylic Acid SCHEMBL15398008 | 0.84 | ALDH1A1 (0.47) | ALDH1A1MEN1CYP1A2KMT2AGGT1 | |
| SCHEMBL8687592 | 0.84 | GGT1 (0.65) | ALDH1A1MEN1CYP1A2KMT2AGGT1 | |
| D-Glutamate SCHEMBL28847437 | 0.83 | CYP1A2 (0.62) | ALDH1A1MEN1CYP1A2KMT2AGGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| US-12589087-B2 | Enantiomer selective action on neurotransmission | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-03-31 | — | — | US | claimed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | claimed |
| CN-117024707-B | Preparation method of hyperbranched epoxy resin and pouring sealant containing hyperbranched epoxy resin | 广东德聚技术股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| US-20240197834-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHRONIC RENAL DISEASE INCLUDING GLUCAGON DERIVATIVE | HANMI PHARM. CO., LTD. (KR) | 2024-06-20 | — | — | US | claimed |
| US-20240115539-A1 | ENANTIOMER SELECTIVE ACTION ON NEUROTRANSMISSION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-04-11 | — | — | US | claimed |
| EP-4321170-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHRONIC KIDNEY DISEASE CONTAINING GLUCAGON DERIVATIVE | Hanmi Pharm. Co., Ltd. (KR) | 2024-02-14 | — | — | EP | claimed |
| EP-4319735-A1 | ENANTIOMER SELECTIVE ACTION ON NEUROTRANSMISSION | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-14 | — | — | EP | claimed |
| EP-4311578-A2 | TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS FOR TREATING LIVER DISEASE | Hanmi Pharm. Co., Ltd. (KR) | 2024-01-31 | — | — | EP | claimed |
| CN-117425472-A | Enantioselective action on neurotransmission | 小利兰·斯坦福大学托管委员会 | 2024-01-19 | — | — | CN | claimed |
| US-5756650-A | COMPOSITION COMPRISING POLYAMIC ACID, CURE ACCELERATOR SELECTED FROM GROUP CONSISTING OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AMINO ACID COMPOUND, AROMATIC COMPOUND HAVING TWO OR MORE HYDROXYL GROUPS | KABUSHIKI KAISHA TOSHIBA (JP) | 1998-05-26 | — | — | US | claimed |
| CN-1030774-C | Process for the preparation of high active detergent particles | PROCTER & GAMBLE (US) | 1996-01-24 | — | — | CN | claimed |
| EP-0539519-B1 | FORMATION OF HIGH ACTIVE DETERGENT PARTICLES | PROCTER & GAMBLE (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0594688-A1 | PROCESS FOR PRODUCING A DETERGENT COMPOSITION CONTAINING ALKYL SULFATE PARTICLES AND BASE GRANULES | THE PROCTER & GAMBLE COMPANY (US) | 1994-05-04 | — | — | EP | claimed |
| EP-0539519-A1 | FORMATION OF HIGH ACTIVE DETERGENT PARTICLES. | PROCTER & GAMBLE (US) | 1993-05-05 | — | — | EP | claimed |
| CN-1070222-A | Preparation contains the method for the detergent composition of alkyl sulfate particles and basic granules | PROCTER & GAMBLE (US) | 1993-03-24 | — | — | CN | claimed |
| WO-1993002168-A1 | PROCESS FOR PRODUCING A DETERGENT COMPOSITION CONTAINING ALKYL SULFATE PARTICLES AND BASE GRANULES | THE PROCTER & GAMBLE COMPANY (US) | 1993-02-04 | — | — | WO | claimed |
| CN-1059366-A | The preparation method of high active detergent granules | PROCTER & GAMBLE (US) | 1992-03-11 | — | — | CN | claimed |
| WO-1992001778-A1 | FORMATION OF HIGH ACTIVE DETERGENT PARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 1992-02-06 | — | — | WO | claimed |
| US-5066425-A | Continuous neutralization of anionic surfactant with alkali metal hydroxide, adding aminodicarboxylic acid | THE PROCTER & GAMBLE COMPANY (US) | 1991-11-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197834-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHRONIC RENAL DISEASE INCLUDING GLUCAGON DERIVATIVE | GLP1R, GCG, GCGR | ALDH1A1 4763/4885MEN1 1853/4885CYP1A2 2666/4885 |
| US-12589087-B2 | Enantiomer selective action on neurotransmission | SLC1A2, GLUL, SLC6A13 | ALDH1A1 147/4885MEN1 3813/4885CYP1A2 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.